Haleon plc

Haleon plc

£373.3
3.6 (0.97%)
London Stock Exchange
GBp, GB
Drug Manufacturers - Specialty & Generic

HLN.L Price Chart

Basic
Market Cap£33.23B
Price£373.3
52 Week Range308.37-400.649
Beta0.24
Margins
Gross Profit Margin60.68%
Operating Profit Margin17.82%
Net Profit Margin9.66%
Valuation (TTM)
P/E Ratio31.49
Price to Sales Ratio3.00
Price to Book Ratio2.06
PEG Ratio0.31

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Full-Time Employees

25,408

IPO Date

2022-07-18T00:00:00.000Z

Description

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.

Phone

44 1932 822000

Address

Building 5, Weybridge, KT13 0NY, GB

CIK